PFAS contamination in cannabis and hemp presents serious health and legal risks. Here's what growers and regulators need to know to protect patients and consumers.

Texas has expanded its medical marijuana law to include chronic pain, TBI, Crohn’s, and more—a major shift in patient access and cannabis policy.

As adult-use cannabis spreads across the U.S., medical marijuana programs are in decline—posing serious implications for patients and providers.

A misconfigured 323 GB database exposed nearly 1 million medical cannabis patient records—names, SSNs, IDs, and health data—in July 2025.

A psychology-based cannabis retail system is helping dispensaries reframe cannabis for clarity, confidence, and emotional wellness.

Discovery of flavoalkaloids in cannabis leaves reveals rare phenolics with antioxidant, anti-inflammatory and anticancer promise.

State audit reveals oversight failures in Massachusetts cannabis regulation, exposing testing lapses, financial errors, and risks to industry equity.

Research shows young adults using high-potency cannabis may not reduce dose. Clear labeling and harm-reduction education can improve safer use.

A large federally funded preprint shows marijuana users aged 44–81 have enhanced cognitive function and younger brain patterns—but causality remains unproven.

Pain, stress, and multiple chronic conditions drive cannabis use—highlighting urgent needs for harm-reduction strategies.

Cannabinoids like CBD and CBDV show promising antifungal activity, offering a safe, effective alternative for treating drug-resistant fungal infections.

New research highlights cannabinoid therapy, specifically combining cannabinol (CBN) with exemestane, as a promising advancement in treating estrogen receptor-positive breast cancer.

THCP, an ultra-potent cannabinoid discovered in 2019, is reshaping cannabis science with its extraordinary receptor affinity and groundbreaking therapeutic potential.